Skip to Main Content
Access your saved content
Mobile health care has gained significant traction and investment from many participants, as pilots and trials evolve to substantively funded business ventures aimed at reaching broad consumer segments.
This white_paper provides examples and options to help biopharmaceutical companies begin developing or refine mHealth strategies and tactics to better serve patients, secure the right collaborators and partners, and deliver improved health solutions.
Watch the Mobile Security Webcast with CIO.com
Explore Mobility Offers
Mobile health care or ”mHealth” has gained significant traction and investment from many participants, as pilots and trials evolve to substantively funded business ventures aimed at reaching broad consumer segments. Early results suggest that mHealth products and services can help meet two important goals: providing high-quality care and reducing costs, particularly in managing chronic diseases.
Summary of key points:
Most mHealth products and services will fall into two types of categories: stand-alone products and services, and comprehensive solutions.
Mobility is a key component of a biopharmaceuticals overall digital strategy and will play a critical role in connecting multiple, currently disparate stakeholders in the health care industry.
As these entities come together, mHealth will go through a maturation process from stand-alone initiatives to becoming a pervasive component in delivering improved health outcomes.
There are three levels of benefits in mHealth for pharmaceutical companies: improved drug compliance; improved health outcomes; and lower health care costs and achieving targeted health outcomes.
We expect most biopharmaceutical companies to pursue the improved health outcomes benefit where they will serve as catalysts in bringing together a community of providers and payers who will be able to influence care delivery to develop mHealth solutions.
Success will require biopharmaceutical companies to craft the right value proposition and obtain reimbursements required to pay for upfront investments and ongoing provider participation. Each market will require different approaches.
There are a myriad of opportunities and levels of involvement for pharmaceutical companies to participate in mHealth. The early part of the mHealth evolution will be primarily characterized by independent, stand-alone solutions but will evolve to a more integrated approach with a blend of stand-alone and comprehensive and will eventually move to a stage where comprehensive solutions that improve patient outcomes will be pervasive.
Biopharmaceutical companies have the relevant capabilities; resources and market reach to play a key role in this evolution. Now is the time to decide what that role will be—to derive the most benefit from related changes and investments.
July 12, 2011
Skip Footer Links